Climb Bio Inc (NASDAQ: CLYM) on Friday, plunged -6.25% from the previous trading day, before settling in for the closing price of $4.0. Within the past 52 weeks, CLYM’s price has moved between $1.05 and $5.05.
Healthcare Sector giant saw their annual sales slid by -40.44% over the last five years. The company achieved an average annual earnings per share of 46.75%. With a float of $62.43 million, this company’s outstanding shares have now reached $68.18 million.
Climb Bio Inc (CLYM) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Climb Bio Inc is 8.44%, while institutional ownership is 45.75%. The most recent insider transaction that took place on Dec 11 ’25, was worth 464,556. In this transaction Director of this company bought 213,099 shares at a rate of $2.18, taking the stock ownership to the 3,294,856 shares. Before that another transaction happened on Dec 12 ’25, when Company’s Director bought 101,462 for $2.86, making the entire transaction worth $290,181. This insider now owns 3,396,318 shares in total.
Climb Bio Inc (CLYM) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.04 earnings per share (EPS) for the period topping the consensus outlook (set at -0.15) by 0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.62% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
Climb Bio Inc (CLYM) is currently performing well based on its current performance indicators. A quick ratio of 18.38 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
As of the previous 9 days, the stock’s Stochastic %D was 10.43%.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 63.00%, which indicates a significant increase from 52.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.66 in the past 14 days, which was higher than the 0.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.56, while its 200-day Moving Average is $1.83. Now, the first resistance to watch is $4.04. This is followed by the second major resistance level at $4.33. The third major resistance level sits at $4.55. If the price goes on to break the first support level at $3.53, it is likely to go to the next support level at $3.31. Now, if the price goes above the second support level, the third support stands at $3.02.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
Market capitalization of the company is 255.69 million based on 68,184K outstanding shares. Right now, sales total 0 K and income totals -73,900 K. The company made 0 K in profit during its latest quarter, and -12,890 K in sales during its previous quarter.
